EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis

Alessandro M. Vannucchi, Peter A.W. te Boekhorst, Claire N. Harrison, Guangsheng He, Marianna Caramella, Dietger Niederwieser, Françoise Boyer-Perrard, Minghui Duan, Nathalie Francillard, Betty Molloy, Monika Wroclawska, and Heinz Gisslinger

Disclosures: AMV reports grants and personal fees from Novartis, during the conduct of the study. PB reports other from advisory board for Novartis and Celgene, outside the submitted work. CNH reports grants and personal fees from Novartis during the conduct of the study; grants and personal fees from Celgene; and personal fees from Shire, Sanofi, Gilead, Incyte, and CTI, outside the submitted work. DN reports grants from Novartis and nonfinancial support from Amgen, outside the submitted work. GH, FB-P, MC, MD, and HG have no conflicts of interest to disclose. NF, BM, and MW are employees of Novartis.

Contributions: AMV, PB, CNH, GH, MC, DN, FB-P, MD, and HG contributed to the collection of data. NF, MW, and BM contributed to the study design. All authors contributed to the analysis of data and drafted and approved the manuscript for submission.